Abstract:ETHNOPHARMACOLOGICAL RELEVANCE: Celastrol is a natural compound extracted from the traditional Chinese medicinal herb, Thunder God Vine (TGV). Owing to its potential anti-inflammatory and antitumor effects, celastrol has been considered as a promising candidate for drug development.AIM OF THE STUDY: To establish a sensitive LC-MS/MS method to investigate the pharmacokinetic properties of celastrol in rats. Key pharmacokinetic issues of celastrol including oral bioavailability, comparative pharmacokinetics between pure compound and tablet preparation, as well as gender-related pharmacokinetic difference are to be addressed for the first time.MATERIALS AND METHODS: Sprague-Dawley rats were administrated an intravenous dose (100 μg kg(-1)) of pure celastrol and an oral dose (1000 μg kg(-1)) of pure celastrol and TGV tablets (corresponding to 534 μg kg(-1) of celastrol), respectively. At different time points, the concentration of celastrol in rat plasma was determined by a sensitive and well-validated LC-MS/MS method. Main pharmacokinetic parameters including area under the plasma concentration-time curve (AUC), maximal plasma concentration (Cmax), the time for maximal concentration (Tmax) and mean residence time (MRT) were estimated by Drug and Statistic1.0 pharmacokinetic software (Chinese Pharmacological Association, Anhui, PR China). Statistical analysis was performed using two one-side t test with p-values less than 0.05 as the level of significance.RESULTS: The standard curve of celastrol showed good linearity in the concentration range of 0.11~54.3 ng mL(-1) in our current method, with acceptable selectivity, precision, recovery, and stability. The oral absolute bioavailability of celastrol significantly increased from 17.06% for pure celastrol to 94.19% for TGV tablets containing equivalent celastrol. After oral administration of TGV tablets, the Cmax and AUC values of celastrol in female rats were (32.03±8.41) μg L(-1) and (379.49±118.19) μg h L(-1), which were significantly higher (p<0.01) than that in males with the values of (14.31±7.33) μg L(-1) and (188.17±92.33) μg h L(-1).CONCLUSION: Celastrol administered orally in the rat was poorly absorbed into the systemic circulation. However, the poor absorption of celastrol could be greatly improved when celastrol-containing TGV tablets orally administered, and thereby the oral bioavailability of celastrol was significantly increased. As for gender difference, female rats showed significantly better absorption of celastrol than males.

A comprehensive study of celastrol metabolism in vivo and in vitro using ultra‐high‐performance liquid chromatography coupled with hybrid triple quadrupole time‐of‐flight mass spectrometry

Determination of Celastrol in Rat Plasma by HPLC

Celastrol: An Update on Its Hepatoprotective Properties and the Linked Molecular Mechanisms

Celastrol Prevents Atherosclerosis Via Inhibiting Lox-1 and Oxidative Stress

Biotransformation of celastrol to a novel, well-soluble, low-toxic and anti-oxidative celastrol-29-O-β-glucoside by Bacillus glycosyltransferases

Biosynthesis, total synthesis, structural modifications, bioactivity, and mechanism of action of the quinone‐methide triterpenoid celastrol

Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies

Celastrol Suppresses Tryptophan Catabolism in Human Colon Cancer Cells As Revealed by Metabolic Profiling and Targeted Metabolite Analysis

Modulation of Lipid Metabolism by Celastrol

Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats

Molecular modulators of celastrol as the keystones for its diverse pharmacological activities

Celastrol suppresses obesity process via increasing antioxidant capacity and improving lipid metabolism

Dissection of Targeting Molecular Mechanisms of Celastrol-induced Nephrotoxicity via A Combined Deconvolution Strategy of Chemoproteomics and Metabolomics

Celastrol: A century-long journey from the isolation to the biotechnological production and the development of an antiobesity drug

Celastrol in metabolic diseases: Progress and application prospects

Characterization of the Cytochrome P450 CYP716C52 in Celastrol Biosynthesis and Its Applications in Engineered Saccharomyces cerevisiae

Design, synthesis, and evaluation of antitumor activity of novel C‐6 sulfhydryl‐substituted and 20‐substituted derivatives of celastrol

Celastrol reduces triglyceride level in HepG2 cells by regulating lipid synthesis and oxidation

Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases

The anti-cancer mechanism of Celastrol by targeting JAK2/STAT3 signaling pathway in gastric and ovarian cancer

Quantitative chemical proteomics reveals anti-cancer targets of Celastrol in HCT116 human colon cancer cells